Table 3.
Correlation between LINC01089 expression levels and clinicopathological features of 748 BC patients in TCGA cohort
| Characteristic | Number of cases | LINC01089 expression | P-value | |
|---|---|---|---|---|
| Low (n=374) | High (n=374) | |||
| Age | 0.026 | |||
| <60 | 436 | 203 | 233 | |
| ≥60 | 312 | 171 | 141 | |
| Tumor size | 0.663 | |||
| ≤2 cm | 191 | 92 | 99 | |
| >2 cm | 557 | 282 | 275 | |
| Lymph node metastasis | 0.003 | |||
| No | 380 | 170 | 210 | |
| Yes | 368 | 204 | 164 | |
| TNM stage | 0.254 | |||
| I-II | 581 | 297 | 284 | |
| III-IV | 167 | 77 | 90 | |
| ER | 0.346 | |||
| Negative | 179 | 84 | 95 | |
| Positive | 569 | 290 | 279 | |
| PR | 0.697 | |||
| Negative | 247 | 121 | 126 | |
| Positive | 501 | 253 | 248 | |
| HER2 | 0.498 | |||
| Negative | 619 | 313 | 306 | |
| Positive | 129 | 61 | 68 | |
Abbreviations: BC, breast cancer; TCGA, The Cancer Genome Atlas; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.